Cargando…
Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data
BACKGROUND: Colorectal cancer (CRC) is one of the main causes of cancer-related deaths in China and around the world. Advanced CRC (ACRC) patients suffer from a low cure rate though treated with targeted therapies. The response rate is about 50% to chemotherapy and cetuximab, a monoclonal antibody t...
Autores principales: | Guo, Gui-Fang, Wang, Yi-Xing, Zhang, Yi-Jun, Chen, Xiu-Xing, Lu, Jia-Bin, Wang, Hao-Hua, Jiang, Chang, Qiu, Hui-Quan, Xia, Liang-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478617/ https://www.ncbi.nlm.nih.gov/pubmed/31057298 http://dx.doi.org/10.3748/wjg.v25.i15.1840 |
Ejemplares similares
-
Beclin 1 and nuclear factor-κBp65 are upregulated in hepatocellular carcinoma
por: KANG, KAI-FU, et al.
Publicado: (2013) -
Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal carcinoma
por: Zhao, Hong, et al.
Publicado: (2017) -
Beclin 1, LC3 and P62 Expression in Equine Sarcoids
por: Martano, Manuela, et al.
Publicado: (2021) -
Role for autophagy-related markers Beclin-1 and LC3 in endometriosis
por: Kong, Zhiwei, et al.
Publicado: (2022) -
Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)